Endocannabinoid Signaling System Explained | Pain Modulation & Therapeutics

Drugs that inhibit the enzymes degrading endocannabinoids (FAAH inhibitors and MAGL inhibitors) can prevent or alleviate neuropathic pain. For example, MAGL inhibitors like JZL184 have been shown to reduce mechanical allodynia and thermal hyperalgesia in animal models. Since peripheral endocannabinoid deficiency is observed in neuropathic pain, administering exogenous 2-arachidonoylglycerol directly to affected peripheral tissues can relieve mechanical allodynia through local action.

The ECS includes enzymes that metabolize or degrade endocannabinoids. The two main enzymes are fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). FAAH primarily metabolizes anandamide, while MAGL primarily metabolizes 2AG. Inhibiting FAAH can potentiate anandamide signaling and produce positive effects of CB1 and CB2 activation, making FAAH an interesting target for novel therapeutic drugs.

The third piece of the endocannabinoid triad includes metabolic enzymes that quickly destroy endocannabinoids within the ECS once they are used. The two big enzymes are fatty acid amide hydrolase (FAAH), which breaks down anandamide, and monoacylglycerol acid lipase (MAGL), which breaks down 2-AG. Endocannabinoids are not stored in the body; once they have served their purpose, enzymes break them down so quickly that it is nearly impossible to know how many cannabinoids are active at any given time.

FAAH inhibitors block endocannabinoid degradation, increasing endocannabinoid levels. Studies showed FAAH inhibition produces antidepressant-like effects similar to desipramine, blocked by rimonabant, and increases prefrontal serotonin firing. A double-blind placebo-controlled trial demonstrated FAAH inhibitors effectively block cannabis withdrawal symptoms, with most benefit on depressive symptoms in chronic users. This suggests endocannabinoid system dysfunction contributes to both cannabis reinforcement and withdrawal-related depression.

Endocannabinoid signaling is tightly regulated by enzymatic degradation: fatty acid amide hydrolase (FAAH) breaks down amide-type endocannabinoids while monoacylglycerol lipase (MAGL) degrades glycerol-type molecules. This degradation prevents persistent signaling and maintains homeostasis. Research employs this understanding to develop therapeutic compounds targeting specific conditions including appetite stimulation (AM6545), neuropathic pain, neuroprotection, peripheral pain, and addiction treatment. The dual approach combines characterizing natural cannabis effects with optimizing synthetic molecules for medical applications, leveraging fundamental discoveries about receptor-ligand interactions and metabolic control.

The endocannabinoid system is not merely a peripheral component but a central system involved in numerous physiological processes: immune response, appetite regulation, sleep, anxiety, emotion, locomotion, cardiovascular and respiratory functions, intraocular pressure, inflammation, reproduction, neural circuit formation, memory formation and extinction, neuroprotection, neurogenesis, motor coordination, thought processes, and creativity. This widespread involvement explains why cannabinoids have such diverse therapeutic potential. The speaker emphasizes that the system serves as a homeostatic modulator, helping the body maintain balance across multiple interconnected physiological processes.

The endocannabinoid system is a biological system in the human body that functions like a lock-and-key mechanism. It consists of receptors (the lock) and endocannabinoids (the key) that the body produces naturally. This system helps maintain homeostasis (balance) in the body. When the system is functioning properly, it helps regulate various physiological processes including mood, appetite, pain sensation, and immune response.

The endocannabinoid system is a biological system in the human body that plays a crucial role in regulating various physiological processes, including mood, appetite, pain sensation, and immune function. This system consists of cannabinoid receptors (CB1 and CB2), endogenous cannabinoids (endocannabinoids) that are naturally produced by the body, and enzymes that synthesize and break down these endocannabinoids. The system helps maintain homeostasis and balance throughout the body, and it is activated by both endogenous compounds and exogenous substances like THC and CBD found in cannabis.

The ECS regulates diverse physiological processes including sleep, energy metabolism, temperature control, pain, inflammation, and immune responses. It influences hunger perception through CB1 receptor activation, as demonstrated by rimonabant's failed anti-obesity trial due to severe psychiatric side effects including increased suicidal ideation. The system protects neurons from excitotoxicity during stress and functions with the reproductive HPT axis to regulate sex hormones. Neurologically, the ECS regulates major neurotransmitters in delicate balance where increasing one typically decreases another. It is involved in learning, attention, memory, and social reward through oxytocin-anandamide interactions. Cortisol negatively correlates with 2-AG levels, but chronic trauma causes glucocorticoid resistance, elevating 2-AG despite high cortisol. This demonstrates complex stress-ECS relationships where prolonged stress leads to dysregulation rather than simple suppression.

The endocannabinoid system (ECS) is the body's master regulator maintaining homeostasis across mood, hunger, sleep, stress, immune response, brain plasticity, learning, metabolism, appetite, digestion, thermogenesis, and addiction. The system comprises two receptor types: CB1 receptors in the brain controlling mood, memory, pain, and appetite; and CB2 receptors in the immune system regulating inflammation. The body produces two primary endocannabinoids: anandamide (AEA), the 'bliss molecule' affecting mood and stress, and 2-AG, a major regulator of pain signaling and inflammation. Three enzymes control endocannabinoid levels: FAAH breaks down anandamide, MAGL breaks down 2-AG, while NAPE-PLD and DAGL synthesize these compounds. Endocannabinoids are produced on demand, mobilized during exercise for mood elevation and pain relief, and respond dynamically to environmental demands.

This comprehensive presentation covers the global landscape of cannabinoid medicine. Four cannabinoid-based medications exist: synthetic THC (1980s), Sativex (CBD+THC for MS), pure CBD for epilepsy (Brazil, 2008), and a THC-rich extract for neuropathic pain (Germany, superior to opioids in Phase 3 trial). Brazil has vanguard legislation but slow implementation; canabidiol is List C1 (less restrictive than morphine). Oral administration presents bioavailability challenges: isolated CBD has only 6% absorption, while lipophilic vehicles increase it to 20-25%. Oral metabolism differs from inhalation, with THC producing more potent active metabolites. Clinical evidence demonstrates no addiction potential - patients on 18mg THC daily for 6 months showed no withdrawal symptoms. Medical indications include anxiety, sleep disorders, inflammatory pain, and multiple sclerosis, with emerging applications in autism, dermatology, and bone growth. Historical evidence dates to ancient China and traditional Indian/Nepalese uses. Modern clinical data shows 40% of cannabinoid patients are women with menopausal symptoms and fibromyalgia. The future includes potential reclassification of CBD and THC, with expectations of significant market growth.

The future of cannabinoid research is in an especially interesting stage. For decades, legal restrictions made it extremely difficult to develop rigorous studies. Limiting access to a substance also limited possibility of researching it, so numerous clinical projects never came to be realized. This scenario is changing. Expansion of medical programs and regulated markets has allowed initiating investigations that until a few years ago were unfeasible. Today large clinical trials, biobanks storing patient samples, and prospective studies capable of following thousands of participants over long periods are beginning to develop.

The host describes the complex regulatory environment for cannabinoid products, which involves multiple overlapping frameworks including food, cosmetic, and pharmaceutical regulations. He explains that CBD products have faced repeated regulatory challenges, including attempts to classify them as psychotropic substances. The host notes that while pharmaceutical development requires years of clinical trials, cosmetic cannabinoid products require relatively faster safety assessments including skin tests and stability testing.

Multiple clinical trials have demonstrated CBD efficacy in drug-resistant epilepsy. The Epidiolex trial (214 patients, 1-30 years) showed 36.5% average seizure reduction, with 39% achieving 50%+ reduction. Patients using Clobazam with CBD showed better response rates (51%). In Dravet syndrome (12 patients, 2-18 years), seizure frequency decreased from 2.4 to 5.9 monthly, with 5% becoming seizure-free. In Lennox-Gastaut syndrome (171 patients, 2-55 years), seizure frequency decreased 43.9% with CBD versus minimal change with placebo. In tuberous sclerosis complex (18 patients), 48.8% seizure reduction was achieved, with 50% classified as responders.

Incanics Healthcare received the 2025 clinical trials arena excellence award for its oral therapy for obstructive sleep apnea, highlighting continued crossover between cannabinoid-based science and traditional biotech development. The company has $70 million in cash and just completed two phase 2 trials, demonstrating the translational potential of cannabis-derived compounds in treating serious medical conditions beyond recreational use.